Submitted:
12 November 2026
Posted:
13 November 2026
You are already at the latest version
Abstract
Bulgaria added two-dose varicella vaccination (12–15 months and 4 years) to its mandatory schedule on 1 July 2026. We estimated the burden of varicella from national administrative data for 2023–2025 and the cost-effectiveness of the programme over 15 years. Notifications, hospital admissions, outpatient visits, reimbursements and sick leave were combined with an age-structured transmission model calibrated to the age distribution of notified cases, with a static comparator that excludes indirect protection. Varicella caused 26,693 notified cases per year (415 per 100,000) and a societal cost of EUR 6.67 million, 87.7% of it lost productivity. The calibrated basic reproduction number was 6.6. The model projected an 83% fall in infections by year 5. From the societal perspective, vaccination was cost-saving and gained 913 discounted QALYs over 10 years, with savings from 2031; the probability of cost-effectiveness at EUR 20,000/QALY was 98%. From the healthcare-payer perspective, the 10-year ICER was EUR 26,505/QALY, and the vaccine price at which it would meet EUR 20,000/QALY was EUR 22.6 per dose. Without indirect protection, the 10-year societal ICER was EUR 18,686/QALY. The programme is good value for Bulgarian society; for the payer it depends on the procurement price.
Keywords:
varicella
; varicella vaccine
; cost-effectiveness analysis
; dynamic transmission model
; herd immunity
; burden of disease
; Bulgaria
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.